Document:

CIGNA CORPORATION - EXHIBIT 10.3

EXHIBIT 10.3
    

	

David M. Cordani 

President and CEO

	
	

 

	

Routing  W2SLT

	

 

	

900 Cottage Grove Road

	

 

	

Hartford, CT 06152

	

 

	

david.cordani@Cigna.com

November 18, 2011 

Matthew G. Manders 

Dear Matt: 

Congratulations on your promotion with Cigna effective November 16, 2011.  I am delighted to confirm your new compensation package as you assume the position of President Regional and Operations. 

•

Base Salary – will increase to a pre-tax annualized rate of $575,000 effective November 21, 2011.  This amount will be reviewed annually based on your performance and pay position relative to the competitive market. 

•

Annual Incentive – your annual target will become $475,000 for the 2011 performance year.  As you are aware, annual incentive is typically paid in the first quarter of the year following the performance period and is not considered earned until the date paid. 

•

Long-Term Incentive – your annual long-term opportunity will become $1,500,000 and will continue to consist of the following two components: 

–

Stock Options – grants are typically awarded in the first quarter each year and may vary from 0 to 200% of target based on individual performance and potential.  Options typically vest over a 3 year period and expire no later than 10 years after grant.  The estimated 2012 annual target is $750,000. 

–

Strategic Performance Shares (SPS) – grants are typically awarded in the first quarter of each year and may vary from 0 to 200% of target based on individual performance.  SPS awards are typically paid or vested three years after the beginning of the performance period.  Awards are not considered earned until the date paid or vested.  The estimated 2012 annual target is $750,000. 

Stock Ownership Guidelines – To align management and shareholder interests Cigna executives are subject to stock ownership guidelines.  Your stock ownership guideline for this position will continue to be 300% of your base salary.   

NEW TOTAL ANNUAL COMPENSATION OPPORTUNITY: $2,550,000 

Also, contingent upon Board Committee approval, the following long-term incentive awards with an estimated present value of $202,245 will be awarded to you:  

•

$7,800 transitional SPU award paid in 2012 (104 units paid at formula with $75 target value per unit) 

•

a transitional SPS award with a grant date value $68,056; shares earned (paid) in 2013 per the plan’s formula 

•

a transitional SPS award with a grant date value $126,389; shares earned (paid) in 2014 per the plan’s formula 

The changes above have no impact on previously awarded bonuses, stock options, SPU or SPS grants.  The compensation program elements – annual incentive, stock options and strategic performance shares are those of our current program and may be subject to modification or enhancement by the Board of Directors.  As an executive of the company, your compensation will be subject to any future program changes. 

Matt, I look forward to continuing to partner with you. 

Sincerely, 

David M. Cordani

DMC/del

cc: K. Gorodetzer

J. Murabitoexhibit10_1.htm

EXHIBIT 10.1

 

**-CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

2012 LIVESTOCK PRODUCTS DISTRIBUTION AGREEMENT

 

This Livestock Products Agreement ("Agreement") effective as of January 1, 2012 ("Effective Date") is made by and between Pfizer Inc, 5 Giralda Farms Madison, New Jersey 07940-1027 ("Pfizer") and MWI VETERINARY SUPPLY COMPANY, 3041 W. Pasadena Drive, Boise, ID 83705 ("MWI").

 

WHEREAS, is in the business of buying and selling animal health products and servicing customers for those products, and

 

WHEREAS, MWI and Pfizer wish to set forth the terms of their relationship related to the purchase and supply of such products,

 

NOW, THEREFORE, in consideration of the promises and covenants contained herein, the parties hereby agree as follows:

 

Definitions:

 

"PARTICIPATING CUSTOMERS" shall mean customers from the list of customers approved by Pfizer who have entered into a Leaders Edge Agreement with Pfizer.

 

"Products" shall mean the Pfizer cattle and swine products sold to MWI by Pfizer pursuant to this Agreement (and referenced in Schedule A to this Agreement).

 

"Sales Out" shall mean the reported sales by MWI to Covansys and accepted by Pfizer.

 

"Strategic Accounts" shall mean all those PARTICIPATING CUSTOMERS listed in Schedule B hereto.

 

1. (a)           Pfizer shall continue to promote its Products to certain select customers in the livestock field. The parties agree that each time a PARTICIPATING CUSTOMER selects MWI as their supplier and to service that customer's account, Pfizer shall send to MWI a Pfizer Suggested Resale Price List which shall specify the Pfizer Products and the Pfizer suggested resale prices quoted to such PARTICIPATING CUSTOMER (hereafter "SUGGESTED RESALE PRICE LIST') Each such SUGGESTED RESALE PRICE LIST shall be incorporated into and become part of this Agreement. Please find the current SUGGESTED RESALE PRICE LIST listed on Schedule C hereto. Also included on Schedule C is the current Pfizer Livestock Distributor Pricing. The Products and suggested resale prices are subject to change at any time in Pfizer's sole discretion upon thirty (30) days prior written notice.

 

(b) Pfizer reserves the right to add or delete PARTICIPATING CUSTOMERS or Strategic Accounts at any time at Pfizer's sole discretion. Pfizer will provide written notice to MWI of any changes. Pfizer will notify MWI of any (i) additions to the Strategic Accounts list within twenty-four (24) hours of Pfizer's receipt of the customer contract and (ii) removals from the Strategic Accounts list within four (4) business days prior to the removal effective date.

 

2. (a)           MWI represents and warrants that for the purposes of this Agreement, it is in the business of purchasing Products from Pfizer for the sole purpose of resale and distribution, is registered within the state(s) with which it does business, is compliant with all pharmacy and distribution licensing requirements within the state(s) with which it does business, and is compliant with and capable of participating in Electronic Data Interchange (EDI).

 

(b) MWI agrees to purchase from Pfizer, at credit terms agreed to between the parties and as may be further set forth on Pfizer's invoices, Products sufficient to fulfill demand from all customers to whom MWI will sell Products in the quantities desired by the customers.

 

(c) MWI agrees to maintain an inventory of Products equal to /**/ Demand per species as identified on Schedule A Cattle and Swine, but excluding all Products indicated on Schedule A as ineligible for RSA payments. For purposes of this Agreement "Demand" shall mean /**/

 

All Products shall count towards the amount held in inventory by MWI. MWI and Pfizer agree to act in good faith to resolve any material differences in the on hand inventory calculations.

 

(d) Pfizer reserves the right to allocate purchases such that MWI may not purchase more than two (2) months MWI's average of the most current Moving Annual Total sales purchases Exceptions must be approved by Pfizer's Animal Health Headquarters.

 

(e) MWI agrees that all sales of Pfizer Products from MWI to a PARTICIPATING CUSTOMER shall reflect the specific prices for each Product provided for in that PARTICIPATING CUSTOMER'S most recent SUGGESTED RESALE PRICE LIST. In the event that the price listed on a PARTICIPATING CUSTOMER'S most recent SUGGESTED RESALE PRICE LIST for any particular Product is lower (at the time of consummation of a sale of such particular Products between MWI and that PARTICIPATING CUSTOMER) than the price paid by MWI to Pfizer for such Product, Pfizer agrees to credit MWI's account for the amount of such difference.

 

3. Nothing herein contained shall create or be deemed to create any relationship between the parties other than as specifically provided for herein. No employment, partnership, specific or general agency relationship shall exist unless specifically provided for in writing between the parties. MWI shall not represent, directly or indirectly, expressly or by implication, that any such relationships exist and/or that MWI has any authority except as set forth in this Agreement.

 

4. MWI shall use commercially reasonable efforts to provide appropriate service to the customers to whom MWI will sell hereunder. For customers serviced pursuant to this Agreement, MWI shall:

 

(a) Store its inventory of Pfizer Products under conditions (including refrigeration where appropriate) in accordance with package labeling or other written instructions from Pfizer to ensure that such Products retain their potency, purity, quality, and identity;

 

(b) Provide to Pfizer by the close of business on each day an EDI 852 report covering all Product inventory purchased from Pfizer and setting forth in dollars at MWI's acquisition cost from Pfizer the amount of inventory by species. MWI agrees that Pfizer shall have the right, upon reasonable advance notice and during business hours to audit inventory in the possession of MWI to confirm compliance with this paragraph 4(b) and to confirm the accuracy of the data contained in the report;

 

(c) Provide to Covansys its Health Industry Number, Customer Health Industry Number, Pfizer Product number, transaction date, ship to zip code, number of units and price with respect to each sale of Product, and unit inventories on each Pfizer Product sku that MWI sells;

 

(d) Provide Sales Out data, which shall include Leaders Edge and Non-Leaders Edge sales, to Covansys within ten (10) working days of the date of each invoice. MWI will use its best efforts to ensure Sales Out data integrity and timeliness;

 

(e) Submit all orders to Pfizer via EDI. EDI report 867 is the acceptable format;

 

(f) MWI shall be prepared to receive EDI 845 contract notification transactions no later than 6/30/2012.

 

(g) Establish any service fee or other charge or discount to any customer including PARTICIPATING CUSTOMERS for Pfizer Products independently and at its sole discretion;

 

(h) Provide regularly scheduled delivery service to its customers and use commercially reasonable efforts to anticipate its customers requirements for Pfizer Products. In the event Pfizer delivers any product order to PARTICIPATING CUSTOMERS (drop ship), no consideration shall be payable to MWI for that order under paragraph 5 below, provided that Pfizer will pay MWI for any drop ship if such shipment is made necessary by the unavailability of Pfizer Products;

 

(i) MWI agrees that credit limits established by Pfizer shall be subject to change upon written notice by Pfizer in its sole discretion and that no Product shipments will be made to MWI in excess of the established credit limits;

 

(j) Invoice customers in an accurate and timely manner;

 

(k) Refer to that PARTICIPATING CUSTOMERS SUGGESTED RESALE PRICE LIST on each invoice for Pfizer Products;

 

(l) Take no action, whether or not identified above, that would harm the Goodwill or name of Pfizer, or damage the interests of Pfizer or the Products, other than where supported by sound factual evidence, including, but not limited to, the diversion of Products and statements of false information. For purposes of this Agreement "Goodwill" shall mean the marketplace advantage of customer patronage and loyalty developed with continuous business under the same name over a period of time; and

 

(m) Make payment to Pfizer for all Products purchased from Pfizer /**/. In the event MWI fails to maintain the inventory levels specified in paragraph 2(c) above Pfizer shall have the right, /**/ written notice to MWI, to receive payment from MWI /**/

 

5. All sales of Products to PARTICIPATING CUSTOMER or Strategic Accounts for whom a SUGGESTED RESALE PRICE LIST has been incorporated into this Agreement are covered by this Agreement with regard to compensation payable to MWI hereunder. Any transaction involving Products with any customer including a PARTICIPATING CUSTOMER for which MWI has not been selected by that PARTICIPATING CUSTOMER as the distributor are not covered by this Agreement with regard to compensation payable hereunder.

 

6. (a)           MWI shall not be provided with any rebate, discount or other compensation for Products handled under this Agreement unless specifically set forth herein. MWI will NOT be eligible to collect an RSA on any lateral sales to an unauthorized Pfizer distributor. (It is MW I's obligation to confirm with Pfizer, prior to making a sale, as to whether a distributor is an authorized distributor.) Further, only product purchased directly from Pfizer by MWI and then sold under the terms of this Agreement will be eligible for any RSA payments described herein. All sales by Pfizer to MWI shall be at the then current Pfizer list price but subject to appropriate credits in accordance with paragraph 2(e). Pfizer shall have the right to raise or change the price of any or all Products to MWI /**/ prior written notice. Pfizer shall be free to limit sales of any or all Products to MWI in advance of any price increase.

 

(b) Only sales out to customers in the continental United States will be eligible for RSA payments.

 

(c) The parties agree that Pfizer shall not be obligated to issue credits for any returns that exceed the current average of returns of distributors as specified below unless such returns are the subject of a recall or made at the request of Pfizer. The current average of returns of distributors for the calendar year of the contract timeline January 1, 2012 to December 31, 2012 shall be:

 

Distributor Average Returns (credits and exchanges) as a % of sales: /**/

 

7. The payments described in Schedule D hereto constitute full and complete compensation for MWI.

 

8. All returns shall be approved by Pfizer and subject to Pfizer's Returned Goods Policy, attached hereto as Schedule F. MWI may not offset payment to Pfizer of invoice amounts as credit for any compensation payable hereunder. Pfizer shall make bi-monthly payments of appropriate fees to MWI.

 

9. MWI and Pfizer agree that, under the specific circumstances delineated in this Section 9, Pfizer, at Pfizer's sole discretion, may recoup the sums outstanding to it from MWI against those sums which may become due from Pfizer to MWI , in that the obligations arise from mutual transactions. The specific circumstances which will enable Pfizer to initiate recoupment are

 

(a) MWI becomes insolvent, which shall be defined as:

 

(i) the sum of MWI's debts is greater than all of MWI's property ("Balance Sheet Test"); or

 

(ii) MWI is generally not paying its debts as they come due; or

 

(iii) MWI has failed to act in good faith for a period in excess of six (6) months to resolve any outstanding invoice or purchase order issues or reconciliations.

 

(b) MWI commences a liquidation of its operations by means of a sale of its assets in their entirety or piecemeal; or

 

(c) MWI ceases its business operations whether or not such cessation is voluntary or involuntary, or;

 

(d) MWI files a proceeding pursuant to the U.S. Bankruptcy Code or any state court proceeding, including an Assignment for the Benefit of Creditors.

 

10. Nothing in this Agreement shall be deemed to preclude MWI from negotiating a service fee or any other consideration from, or providing any discount or rebate to, any customer, including PARTICIPATING CUSTOMERS for any services provided by MWI.

 

11. MWI shall distribute Pfizer Products only under the labeling provided by Pfizer or as otherwise approved in writing by Pfizer; prescribe, recommend, suggest, and advertise each Product for use only under the conditions stated in the labeling provided by Pfizer; and observe all federal, state, and local laws governing the distribution of the Products.

 

12. Nothing in this Agreement shall be deemed to limit Pfizer's ability to sell any Product at any time to any customer including PARTICIPATING CUSTOMERS or any other party. Transactions consummated directly between Pfizer and any such customer or other party shall not qualify for any of the compensation payable to MWI hereunder. Nothing in this Agreement shall be deemed to limit MWI's ability to sell non-Pfizer products at any time to any customer including PARTICIPATING CUSTOMERS or any other party. MWI's active promotion or sale of products not made by Pfizer will not be considered harmful to the Goodwill or name of Pfizer, or the Products, provided that the Pfizer Products are not maligned in any way as prohibited under Section 4(k) of this Agreement.

 

13. EXCEPT AS SET FORTH IN THIS AGREEMENT, IN THE LABELING OF THE PRODUCTS SOLD HEREUNDER, OR AS OTHERWISE SPECIFIED IN WRITING BY PFIZER, PFIZER MAKES NO EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO THE PRODUCTS.

 

(a) Pfizer shall defend, indemnify, and hold MWI harmless from all liabilities, claims, demands, damages, costs and expenses, or money judgments incurred by MWI or rendered against it resulting from (a) any breach by Pfizer of this Agreement, (b) third party claims or actions for personal injury or property damage which arise out of the distribution or sale of Pfizer products or the failure to warn, except to the extent that such personal injury or property damage arises out of the negligence or willful misconduct of MWI, and (c) any claim that the Products, as sold by Pfizer, were defective. In the event Pfizer is found by any court of competent jurisdiction to be liable for any claim based in products liability, then Pfizer shall reimburse MWI's reasonable legal fees incurred in the course of cooperating with Pfizer's defense. To be covered by this defense and indemnity, MWI must: promptly notify Pfizer of any such claim; allow Pfizer to fully control the defense and/or resolution of the claim; and cooperate fully with Pfizer in the matter. This defense, indemnity and payment for legal fees shall not apply to claims alleging: MWI alteration, negligent handling or improper storage of the Products; sale of outdated Products; sale or recommendation of the Products for uses or in a manner not set forth in either the labeling supplied by Pfizer or as otherwise specified by Pfizer in writing; or sale of the Products after receipt of written notice from Pfizer that such sales should be halted.

 

(b) In no event shall either party be liable to the other party for special, collateral, incidental, punitive or consequential damages in connection with or arising out of this Agreement. Except as provided under subparagraph 14(a), above, total damages recoverable against Pfizer by MWI shall be exclusively limited to the purchase price of the Products with respect to which damages are claimed.

 

14. MWI and Pfizer acknowledge that in the performance of their duties hereunder each may obtain access to "Confidential Information" (as defined below) of the other. MWI and Pfizer agree that during the term of this Agreement and for a period of three (3) years after the termination of this Agreement, unless specifically permitted in writing by the other party, which permission shall not be unreasonably withheld, especially in connection with a sale of all or a substantial portion of MWI's business, to (a) retain in confidence and not disclose to any third party and (b) use only for the purpose of carrying out their duties hereunder, any such Confidential Information. As used herein the term "Confidential Information" means any information, or data, whether of a business or scientific nature and whether in written, oral or tangible form, relating to Pfizer's and MWI's business or potential business or its research and development activities, not generally available to or known to the public, and not otherwise known to the receiving party, that is disclosed to or learned by the other party pursuant hereto. "Confidential information" does not mean or include any information: (a) which is, at the time of disclosure, available to the general public; or (b) which following disclosure becomes available to the general public through no fault of the recipient; or (c) which recipient can demonstrate was in its possession before receipt; or (d) which is disclosed to recipient without restriction on disclosure. Upon written request from either party after completion of the work provided for hereunder or other termination of this Agreement each party will return to the other party any documents, or copies thereof, or any product samples, containing or constituting Confidential Information disclosed to or generated by either party in connection with this Agreement.

 

15. All notices or communications given hereunder by one party to the other shall be sent by hand or by first class prepaid registered or recorded delivery post or by facsimile addressed to such party as follows:

 

If to Pfizer:

Pfizer, Inc

Attention: President, Animal Health 5 Giralda Farms

Madison, New Jersey 07940 - 1027

 

If to MWI VETERINARY SUPPLY COMPANY.

MWI VETERINARY SUPPLY COMPANY Attention: Jim Cleary

3041 W Pasadena Drive

Boise, ID 83705

Either party may change its address by giving written notice to the other party.

 

16. This Agreement shall be effective as of January 1, 2012 and shall continue in force until December 31, 2012. This Agreement may be terminated by either party upon thirty (30) days prior written notice. Such termination may be without cause. This Agreement may be terminated immediately by either party upon written notice in the event of a material breach by the other. In the event MWI takes any action that harms or damages the interests of Pfizer or the Products, other than where supported by sound factual evidence, including, but not limited to, the diversion of Products and statements of false information, Pfizer may terminate this Agreement immediately upon written notice

 

17. This Agreement shall governed by the laws of the State of New York applicable to contracts made and performed therein. This Agreement is not assignable without the express written consent of the other party, and may be modified or amended only in writing signed by both parties.

 

18. This Agreement and documents referred to herein embody the entire understanding between the parties hereto, will supersede prior agreements relating to the Products.  No activities conducted pursuant to this Agreement or related thereto, including but not limited to the future planning activities of the parties, shall be deemed to give rise to any obligations on the part of either party other than as expressly provided for herein.

 

IN WITNESS WHEREOF, intending to be legally bound, the parties have executed this Agreement.

 

	
MWI VETERINARY SUPPLY COMPANY

BY:                    /s/ Mary Pat Thompson

Name:                  Mary Pat Thompson 

Title:                    SVP and CFO

Date:                    January 27, 2012

	
Pfizer Inc.

BY:         /s/ Clinton A. Lewis, Jr.                                                   

Clinton A. Lewis, Jr.

President, U.S. Operations

Pfizer Animal Health

Date:             February 13, 2012 

SCHEDULE A

 

2012 LEADER’S EDGE RSA ELIGIBILITY LIST

 

	
SKU

	
ITEM DESCRIPTION

	  	
SIZE

	
RSA

ELIGIBLE

	
RSA

(Sales to LE

Vets & Animal

Health

Accounts)

	
RSA

(Sales to

Strategic

Producers)

	
RSA

Sales to

LE

Producers

	
CATTLE-BIOLOGICALS

	
4252

	
Bovi-Shielde BRSV

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4256

	
Bovi-Shield BRSV

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5194

	
Bovi-Shield GOLD® 4

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5195

	
Bovi-Shield GOLD 4

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5199

	
Bovi-Shield GOLD® 5

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
5196

	
Bovi-Shield GOLD 5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5197

	
Bovi-Shield GOLD 5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5321

	
Bovi-Shield GOLD® FP® 5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5322

	
Bovi-Shield GOLD FP 5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5323

	
Bovi-Shield GOLD® FP® 5 L5

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
5324

	
Bovi-Shield GOLD FP 5 L5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5325

	
Bovi-Shield GOLD FP 5 L5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5326

	
Bovi-Shield GOLD® FP® 5 VL5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5327

	
Bovi-Shield GOLD FP 5 VL5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5044

	
Bovi-Shield GOLD® FP® 5 L5 HB

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
5253

	
Bovi-Shield GOLD FP 5 L5 HB

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5254

	
Bovi-Shield GOLD FP 5 L5 HB

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5255

	
Bovi-Shield GOLD® FP@ 5 VL5 HB

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5256

	
Bovi-Shield GOLD FP 5 VL5 HB

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5267

	
Bovi-Shield GOLD@ BVD

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5268

	
Bovi-Shield GOLD BVD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5269

	
Bovi-Shield GOLD® IBR-BVD

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5191

	
Bovi-Shield GOLD IBR-BVD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4179

	
Bovi-Shield@ IBR

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4002

	
Calf-Guard®

	  	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
4143

	
CattleMastera 4+VL5

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
4144

	
CattleMaster 4+VL5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4145

	
CattleMaster 4+VL5

	  	
25

	
/**/

	
/**/

	
/**/

	
/**/

	
5094

	
CattleMaster@ GOLDTm FP@ 5

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
5095

	
CattleMaster GOLD FP 5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5096

	
CattleMaster GOLD FP 5

	  	
25

	
/**/

	
/**/

	
/**/

	
/**/

	
5124

	
CattleMastere GOLDTm FP@ 5 L5

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
5125

	
CattleMaster GOLD FP 5 L5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5126

	
CattleMaster GOLD FP 5 L5

	  	
25

	
/**/

	
/**/

	
/**/

	
/**/

	
1434

	
E.coli Bacterin- J5TM Strain

	  	
20

	
/**/

	
/**/

	
/**/

	
/**/

	
1435

	
E.coli Bacterin- J-5 Strain

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5263

	
INFORCETM3

	  	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
5264

	
INFORCE 3

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5265

	
INFORCE 3

	  	
25

	
/**/

	
/**/

	
/**/

	
/**/

	
5266

	
INFORCE 3

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4475

	
Leptoferm-5®

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

 

	
SKU

	
ITEM DESCRIPTION

	  	
SIZE

	
RSA

ELIGIBLE

	
RSA

(Sales to LE

Vets & Animal

Health

Accounts)

	
RSA

(Sales to

Strategic

Producers)

	
RSA

Sales to

LE

Producers

	
4477

	
Leptoferm-5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4988

	
One Shot®

	  	
5

	
/**/

	
/**/

	
/**/

	
/**/

	
4991

	
One Shot

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4993

	
One Shot

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5074

	
One Shot Ultra® 7

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5075

	
One Shot Ultra 7

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5076

	
One Shot Ultra® 8

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5077

	
One Shot Ultra 8

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5328

	
PregGuard® GOLD FP® 10

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5329

	
PregGuard GOLD FP 10

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4308

	
Resvac® 4/Somubac®

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4307

	
Resvac 4/Somubac

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5331

	
ScourGuard® 4K

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5332

	
ScourGuard 4K

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5333

	
ScourGuarde 4KC

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5334

	
ScourGuard 4KC

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4255

	
Somubac®

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4254

	
Somubac

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5088

	
Spirovac®

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5090

	
Spirovac

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5200

	
Spirovac® L5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5201

	
Spirovac L5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5202

	
Spirovac® VL5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5203

	
Spirovac VL5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4890

	
StayBred TM VL5

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4892

	
StayBred VL5

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4904

	
TSV-2®

	  	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
4909

	
TSV-2

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4912

	
TSV-2

	  	
25

	
/**/

	
/**/

	
/**/

	
/**/

	
4913

	
TSV-2

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4381

	
Ultrabac® 7

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4379

	
Ultrabac 7

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4380

	
Ultrabac 7

	  	
200

	
/**/

	
/**/

	
/**/

	
/**/

	
4384

	
Ultrabac® 7/Somubac®

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4382

	
Ultrabac 7/Somubac

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4383

	
Ultrabac 7/Somubac

	  	
200

	
/**/

	
/**/

	
/**/

	
/**/

	
4387

	
Ultrabac-8®

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4385

	
Ultrabac-8

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4386

	
Ultrabac-8

	  	
200

	
/**/

	
/**/

	
/**/

	
/**/

	
4388

	
Ultrabac® CD

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
4371

	
Ultrabac CD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5062

	
UltraChoice® 7

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5063

	
UltraChoice 7

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5064

	
UltraChoice 7

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5065

	
UltraChoice® 8

	  	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
5066

	
UltraChoice 8

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

 

 

	
SKU

	
ITEM DESCRIPTION

	  	
SIZE

	
RSA

ELIGIBLE

	
RSA

(Sales to LE

Vets & Animal

Health

Accounts)

	
RSA

(Sales to

Strategic

Producers)

	
RSA

Sales to

LE

Producers

	
5067

	
UltraChoice 8

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5061

	
UltraChoice® CD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4937

	
Vibrin®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5330

	
SolidBac® Pinkeye IR/PR®

	  	
1 Pouch of

50

	
/**/

	
/**/

	
/**/

	
/**/

	
5270

	
Salmonella NewPort Bacterial Extract

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5271

	
Escherichia Coli Bacterial Extract

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
  CATTLE-ANTI-INFECTIVES

	  	
8171

	
A180®

	
Rx

	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8172

	
A180

	
Rx

	
250 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8448

	
Albon® Bolus

	  	
5 g x 50

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8449

	
Albon Bolus

	  	
15 g x 12

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8450

	
Albon Bolus

	  	
15 g x 50

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8189

	
Draxxin® Injectable Solution

	
Rx

	
50 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8174

	
Draxxin Injectable Solution

	
Rx

	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8175

	
Draxxin Injectable Solution

	
Rx

	
250 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
8176

	
Draxxin Injectable Solution

	
Rx

	
500 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1506

	
Excede® Sterile Suspension

	
Rx

	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1431

	
Excenel® RTU Sterile Suspension

	
Rx

	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1531

	
Excenel® RTU Sterile Suspension

	
Rx

	
250 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
7959

	
Liquamycin® LA-200®

	  	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
7960

	
Liquamycin LA-200

	  	
250 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
7961

	
Liquamycin LA-200

	  	
500 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1465

	
Naxcel® Sterile Powder

	
Rx

	
1 g

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1466

	
Naxcel Sterile Powder

	
Rx

	
4 g

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1463

	
Sterile Water

	  	
80 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
1464

	
Sterile Water

	  	
20 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  	
7948

	
Terramycirt® Scour Tabs

	  	
250 mg,

24/btl

	
/**/

	
/**/

	
/**/

	
/**/

	  	
7949

	
Terramycin Scour Tabs

	  	
250 mg,

100/btl

	
/**/

	
/**/

	
/**/

	
/**/

 

	  	
  CATTLE-LINCOMIX

	
1453

	
Lincomix® Soluble Powder

	  	
480 g

	
/**/

	
/**/

	
/**/

	
/**/

	
1436

	
Linco-Spectin®

	
Rx

	
20 mL

	
/**/

	
/**/

	
/**/

	
/**/

	
  CATTLE-MASTITIS

	
1403

	
Albadry Plus®

	  	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
1404

	
Albadry Plus

	  	
144

	
/**/

	
/**/

	
/**/

	
/**/

	
2004

	
Nolvasan® Teat Dip

	  	
1 gal

	
/**/

	
/**/

	
/**/

	
/**/

	
8169

	
Orbeseal®

	  	
144

	
/**/

	
/**/

	
/**/

	
/**/

	
1475

	
Pirsue® Sterile Solution

	
Rx

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
1476

	
Pirsue Sterile Solution

	
Rx

	
144

	
/**/

	
/**/

	
/**/

	
/**/

	
1480

	
Quartermaster®

	
Rx

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
1481

	
Quartermaster (Bulk Pack)

	
Rx

	
144

	
/**/

	
/**/

	
/**/

	
/**/

	
1507

	
Spectramast® LC

	
Rx

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
1510

	
Spectramast LC

	
Rx

	
144

	
/**/

	
/**/

	
/**/

	
/**/

	
1508

	
Spectramast® DC

	
Rx

	
12

	
/**/

	
/**/

	
/**/

	
/**/

 

 

	
SKU

	
ITEM DESCRIPTION

	  	
SIZE

	
RSA

ELIGIBLE

	
RSA

(Sales to LE

Vets & Animal

Health

Accounts)

	
RSA

(Sales to

Strategic

Producers)

	
RSA

Sales to

LE

Producers

	
1511

	
Spectramast DC

	
Rx

	
144

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
CATTLE-PARACITICIDES

	
7897

	
Dectomax® 1% Injectable

	  	
100 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
8186

	
Dectomax 1% Injectable

	  	
200 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
7899

	
Dectomax 1% Injectable

	  	
500 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
7892

	
Dectomax® Pour-On

	  	
250 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
7893

	
Dectomax Pour-On

	  	
1L

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
7894

	
Dectomax Pour-On

	  	
2.5 L

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
7895

	
Dectomax Pour-On

	  	
5L

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
7030

	
Durasect®

	  	
1 gal

	
/**/

	
/**/

	
/**/

	
/**/

	
7032

	
Durasect® II

	  	
900 mL

	
/**/

	
/**/

	
/**/

	
/**/

	
8783

	
Valbazen®

	  	
500 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
8784

	
Valbazen

	  	
1L

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
8785

	
Valbazen

	  	
5L

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
  CATTLE-REPRODUCTION

	
1420

	
EAZI-BreedTM CIDR® Applicator

	  	
Applicator

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
1518

	
EAZI-Breed CIDR Green Applicator

	  	
Applicator

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
1421

	
EAZI-Breed CIDR Insert

	  	
Bag of 10

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
0135

	
EAZI-BreedTM CIDR® G Applicator (Sheep)

	  	
Applicator

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
1533

	
EAZI-Breed CIDR G Insert (Sheep)

	  	
Bag of 20

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
2001

	
Factrel®

	
Rx

	
20 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
1455

	
Lutalyse® Sterile Solution

	
Rx

	
30 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
1504

	
Lutalyse Sterile Solution

	
Rx

	
100 mL

	
/**/

	
       /**/

	
       /**/

	
       /**/

	
  CATTLE-OTHER PHPARMACEUTICALS

	
8152

	
Entrolyte® H.E.

	  	
178 g

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2002

	
Hog & Cattle Vitamins & Electrolytes

	  	
8 oz

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1478

	
Predef® 2X

	
Rx

	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
8112

	
Re-Sorb®

	  	
12

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
8142

	
Re-Sorb

	  	
72

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
8620

	
Therabloat®

	  	
2 oz

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
  CATTLE-PRODUCTION

	
1458

	
MGA® 200 Premix

	  	
50 lb bag

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1459

	
MGA® 500 Liquid Premix

	  	
40 lb drum

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2016

	
Synovex® C

	  	
Box(10-10

ds Clips)

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2014

	
Synovex C

	  	
Display(20

x 2-10 ds

Clips)

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2017

	
Synovex® Choice

	  	
Box(10-10

ds Clips)

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2018

	
Synovex® H

	  	
Box(10-10

ds Clips)

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2019

	
Synovex® Plus

	  	
Box(10-10

ds Clips)

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2022

	
Synovex® S

	  	
Box(10-10

ds Clips)

	
/**/

	
/**/

	
/**/

	
/**/

	  

 

 

	
SKU

	
ITEM DESCRIPTION

	  	
SIZE

	
RSA

ELIGIBLE

	
RSA

(Sales to LE

Vets & Animal

Health

Accounts)

	
RSA

(Sales to

Strategic

Producers)

	
RSA

Sales to

LE

Producers

	
SWINE RESPIRATORY BIOLOGICALS

	
5275

	
FluSure XP®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5276

	
FluSure XP

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5042

	
FluSure® Pandemic

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5043

	
FluSure Pandemic

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5272

	
FluSure XP®/FarrowSure® GOLD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5273

	
FluSure XP/FarrowSure GOLD

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5274

	
FluSure XP®/FarrowSure® GOLD Plus B

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5278

	
FluSure XP®/RespiSure®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5279

	
FluSure XP®/RespiSure-ONE®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5225

	
FluSure XP®/ER Bac Plus®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5280

	
FluSure XP®/RespiSure-ONE®/ER Bac Plus®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
2218

	
Fostera PCV

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
2219

	
Fostera PCV

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5260

	
RespiSure-ONE®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5261

	
RespiSure-ONE

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5262

	
RespiSure-ONE

	  	
500

	
/**/

	
/**/

	
/**/

	
/**/

	
5166

	
RespiSure-ONE®/ER Bac Plus®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5167

	
RespiSure-ONE/ER Bac Plus

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5168

	
RespiSure-ONE/ER Bac Plus

	  	
500

	
/**/

	
/**/

	
/**/

	
/**/

	
4606

	
RespiSure®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4618

	
RespiSure

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
4589

	
RespiSure

	  	
500

	
/**/

	
/**/

	
/**/

	
/**/

	
5169

	
RespiSure®/ER Bac Plus®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5170

	
RespiSure/ER Bac Plus

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5171

	
RespiSure/ER Bac Plus

	  	
500

	
/**/

	
/**/

	
/**/

	
/**/

	
2238

	
Suvaxyn® RespiFend® MH/HPS

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
2239

	
Suvaxyn RespiFend MH/HPS

	  	
125

	
/**/

	
/**/

	
/**/

	
/**/

	
5041

	
ER Bac® Plus

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
2214

	
Suvaxyn® E - oral

	  	
100

	
/**/

	
/**/

	
/**/

	
/**/

	
2215

	
Suvaxyn E - oral

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
2216

	
Suvaxyn E - oral

	  	
500

	
/**/

	
/**/

	
/**/

	
/**/

	
SWINE REPRODUCTIVE BIOLOGICALS

	
5213

	
ER Bac® L5 GOLD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5204

	
FarrowSure® GOLD

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
5248

	
FarrowSure GOLD

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
5206

	
FarrowSure® GOLD B

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4402

	
LitterGuard®

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4410

	
LitterGuard® LT-C

	  	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
4452

	
LitterGuard LT-C

	  	
250

	
/**/

	
/**/

	
/**/

	
/**/

	
SWINE LARGE ANIMAL VIALS

	
8189

	
Draxxin® Injectable Solution

	
Rx

	
50 mL

	
/**/

	
/**/

	
/**/

	
/**/

	
8174

	
Draxxin Injectable Solution

	
Rx

	
100 mL

	
/**/

	
/**/

	
/**/

	
/**/

	
8175

	
Draxxin Injectable Solution

	
Rx

	
250 mL

	
/**/

	
/**/

	
/**/

	
/**/

 

 

	
SKU

	
ITEM DESCRIPTION

	  	
SIZE

	
RSA

ELIGIBLE

	
RSA

(Sales to LE

Vets & Animal

Health

Accounts)

	
RSA

(Sales to

Strategic

Producers)

	
RSA

Sales to

LE

Producers

	
8176

	
Draxxin Injectable Solution

	
Rx

	
500 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1505

	
EXCEDE® for Swine

	
Rx

	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1431

	
Excenel® RTU Sterile Suspension

	
Rx

	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1531

	
Excenel® RTU Sterile Suspension

	
Rx

	
250 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1436

	
Linco-Spectin®

	
Rx

	
20 mL

	
/**/

	
/**/

	
/**/

	
/**/

	
1450

	
Lincomix® 100 mg Injectable

	  	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1451

	
Lincomix 300 mg Injectable

	  	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1455

	
Lutalyse® Sterile Solution

	
Rx

	
30 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1504

	
Lutalyse Sterile Solution

	
Rx

	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1465

	
Naxcel® Sterile Powder

	
Rx

	
1 g

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1466

	
Naxcel Sterile Powder

	
Rx

	
4 g

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1463

	
Sterile Water

	  	
80 mL

	
/**/

	
/**/

	
/**/

	
/**/

	
1478

	
Predef® 2X

	
Rx

	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
7897

	
Dectomax® 1% Injectable

	  	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
8186

	
Dectomax 1% Injectable

	  	
200 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
7899

	
Dectomax 1% Injectable

	  	
500 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
7959

	
Liquamycin® LA-200®

	  	
100 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
7960

	
Liquamycin LA-200

	  	
250 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
7961

	
Liquamycin LA-200

	  	
500 mL

	
/**/

	
       /**/

	
       /**/

	
/**/

	
1453

	
Lincomix® Soluble Powder

	  	
480 g

	
/**/

	
/**/

	
/**/

	
/**/

	
1454

	
LS 50

	  	
75 g

	
/**/

	
/**/

	
/**/

	
/**/

	
SWINE-FEED MEDICATIONS

	
1447

	
Lincomix® 20

	  	
50 lb

	
/**/

	
/**/

	
/**/

	
/**/

	
1448

	
Lincomix® 50

	  	
50 lb

	
/**/

	
/**/

	
/**/

	
/**/

 

SCHEDULE B

LIST OF STRATEGIC ACCOUNTS

“PARTICIPATING CUSTOMERS” (Veterinarians, Dealers, Producers, and Strategic Producers) will be clearly identified with

 

current updates within the Leaders’ Edge Enrollment Notifications that are regularly posted to the Pfizer AH Partners website

 

www/pfizerahartners.com.

 

	
NARC ID

	
NARC Name

	
NARC Address

	
NARC City

	
NARC State

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

 

	
NARC ID

	
NARC Name

	
NARC Address

	
NARC City

	
NARC State

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

 

 

	
NARC ID

	
NARC Name

	
NARC Address

	
NARC City

	
NARC State

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

 

 

SCHEDULE C

SUGGESTED RESALE PRICE LIST AND DISTRIBUTOR PRICING

CATTLE AND SWINE SUGGESTED RETAIL PRICING

Pricing is provided on Pfizer’s website

 

 

SCHEDULE D

 

 

Section A

 

Fee for Logistics

 

	
  

	
Definitions: "Fee Eligible Products" shall mean those Pfizer Products listed in Schedule A hereto for which a Fee payment will be made to MWI in accordance with paragraph 5.

 

1) Pfizer shall pay to MWI a fee for logistics (hereinafter, "Fee") paid at a rate of (i) a differentiated percentage [see SCHEDULE E for breakdown] on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are producers (but not including Strategic Accounts), (ii /**/ on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are veterinarians (but not including Strategic Accounts), and (iii) /**/ on Sales Out for Fee Eligible Products to identified PARTICIPATING CUSTOMERS who are Strategic Accounts. For a Veterinarian to receive an RSA on Strategic Producer product sales, the Veterinarian must buy those product quantities directly from Pfizer Animal Health. Such product purchases must be made within the timeframe of the reported sales to the Strategic Producer in order to receive a /**/ for sales to Leaders' Edge Strategic Producers. The Veterinarian also must hold the accounts receivable on those products for the Strategic Producer. The remaining product purchases to service Leaders' Edge accounts or Non-Leaders' Edge accounts may be sourced from an authorized Pfizer distributor or directly from Pfizer Animal Health. The Fee is calculated on a Product by Product basis and based on the Product price contained in the Participating Customer's SUGGESTED RESALE PRICE LIST in effect at the time of such Product purchase. The Fee is contingent on MWI fulfilling all conditions outlined in paragraph 4 of this Agreement. The payments made pursuant to this Schedule D, Section A are not payable for sales to anyone other than PARTICIPATING CUSTOMERS. The Fee is net of any difference between MWI's purchase price and the SUGGESTED RESALE PRICE LIST price. MWI shall only receive the payments set out in this Schedule D, Section A for sales to PARTICIPATING CUSTOMERS which are consummated after confirmation by Pfizer to MWI that a customer is a PARTICIPATING CUSTOMER.

 

2) Pfizer shall have the right to audit shipping records of MWI to confirm delivery of Products to producers or veterinarians in order to assure proper Fee payments under paragraph 1 of this Schedule D, Section A. Any material misrepresentations by MWI related to paragraph 1 of this Schedule D, Section A and the party actually taking possession of the products shall void any payments due under paragraph 1 of this Schedule D, Section A In addition, MWI recognizes that the Leaders Edge program is designed as an effective go-to market approach to selling for the benefit of veterinarians and/or dealers who add value in the transaction to their customers as well as value for those customers. Blatant abuse of the intended structure of the Leaders Edge Program by MWI (including, but not limited to, falsification of EDI data or establishing false business entities or inserting business entities that add no commercial value to end users purely to obtain additional Fee payments) will subject MWI to potential forfeiture of all Fee's paid on those transactions provided for in this Schedule D, Section A at the sole discretion of Pfizer. Decisions made as a result of Pfizer's investigations of blatant abuse of the intended structure of Leaders Edge are solely Pfizer's to make and forfeitures of Fees may happen retroactively in the form of credits against future Fee payments.

 

3) The parties agree that MWI will provide to Pfizer on request and within two (2) business days, proof of delivery on any suspicious (as determined by Pfizer) EDI transaction. MWI agrees that Pfizer shall be entitled to audit, either directly or through external auditors hired by Pfizer and upon reasonable notice by Pfizer, MWI's books and records for the purpose of determining the accuracy of EDI data for Pfizer Product sales communicated to Pfizer through Covansys.

Products which are not listed in Schedule A do not qualify for Fee payments. All such Products shall be purchased by MWI on a buy sell basis If new sku's are added to Schedule A, Pfizer will communicate this to MWI on a quarterly basis.

 

 

4) Products which are not listed in Schedule A do not qualify for Fee payments. All such Products shall be purchased by MWI on a buy sell basis If new sku's are added to Schedule A, Pfizer will communicate this to MWI on a quarterly basis.

 

SCHEDULE E

Cattle Swine Leaders Edge/Differentiated RSA

 

 

Effective January 1, 2012 through December 31, 2012 Leaders' Edge Suppliers will receive a service fee (RSA) for sales to eligible Leaders' Edge customers as indicated below.

 

RSA Payments

 

	
Sales To ->

	
LE Vet/Dealer

	
LE Strategic

Producer

	
LE Producer

	
Distributor

	
/**/

	
/**/

	
Variable RSA (See

Schedule A)

	
Veterinarian

	
/**/

	
/**/

	
Variable RSA (See

Schedule A)

 

** Veterinarians MUST purchase an equivalent amount of product direct from Pfizer Animal Health to be eligible for a /**/ for sales to Leaders' Edge Strategic Producers.

 

 

 

 

SCHEDULE F

Pfizer Returned Goods Policy and Procedure

 

 

AUDIENCE

 

Customer Service Operations, Finance, Marketing, & Field Force SCOPE

Cattle, Swine, Equine, and CAD products purchased directly from Pfizer Animal Health may be returned for credit based on the current Pfizer Animal Health Return Goods Price List providing it is not outside the defined return window. ONLY CAD products may be returned for exchange providing it is not outside the defined return window.

 

o Cattle, Swine, Equine, and CAD products return window is defined as two months prior and six months beyond the product's expiration date. (except Revolution 6pk and Rimadyl 180ct, which can be exchanged or credited six months prior to the products expiration date).

 

o In addition, CAD products may also be returned 12 months after the invoice date for Return Goods Credit only provided that the product has not expired.

 

Cattle, Swine, and Equine Biologicals purchased directly from Pfizer Animal Health may be returned for credit based upon 100% of the customer's prior calendar year's pricing. All other Cattle, Swine, and Equine products will receive credit based upon 90% of the customer's prior calendar year's pricing.

 

o Exception #1: Short dated products (defined as consistently shipping with

4-6months dating or less, such as ScourGuard) may receive a return goods credit based upon 100% of customer's current year's pricing.

o Exception #2: Newly launched products not available the prior year, will

follow the return policy as stated above but pricing will be based off of the current year.

 

Cad Products purchased directly from Pfizer Animal Health may be returned for credit at 75% of current list price or be exchanged for like product in full packaged quantities provided they are within the return window.

 

oException #1: Customers that receive discount pricing due to a contract may have terms

per their contract stating they will receive returns pricing at 75% of invoice price.

 

Products sold on a non-returnable basis are not eligible for credit or exchange. Products sold on a non­returnable basis include: syringes, rabies tags, Unipet Nutritabs, Roccal-D, Plastic Dispensing Bags, Sterile Water, Terramycin-343, Terramycin Soluble Powder, Eazi-Breed CIDR, Lincomix Soluble Powder, Lincomix Feed, Neomix 325 Commercial Grade, LS 50, and MGA

 

A.                 Products NOT eligible for exchange include:

 

1         Products not purchased directly from Pfizer Animal Health

2         Cattle, Swine, and Equine Products

 

3         Products outside the defined return window

4         Items returned in less than the original packaged unit (partials)

 

B.                 Products NOT eligible for credit include:

 

1Products not purchased directly from Pfizer Animal Health

2Products outside the defined return window

3Items returned in quantities less than the original packaged unit (partials),

with the exception of small animal biologicals, Amoxi tablets, Clavamox tablets, Albon tablets, Primor, Zeniquin, Cestex, Anipryl, and Temaril-P.

Partial returns of these items will be credited in 25% increments.

 

	
  

	
C.

	
Claims for Breakage or Shortage - Any obvious breakage or shortage must be brought to the attention of Pfizer Animal Health and the carrier. This must also be noted when signing delivery documents. Mis-shipments, shortages and concealed damages must be reported to Pfizer Animal Health within 15 business days for distribution (21 days for Veterinarians) from invoice date to receive full invoice credit. Claims received after this timeframe will not be considered for credit. Credits for damages and mis-shipments (i.e. CSR or warehouse error) will be matched up to the original invoice and credited at full invoice pricing.

 

	
  

	
D.

	
Discontinued Products - Discontinued products may not be returned for exchange but can be returned for credit at our current retum's price. Return of discontinued product must meet all other return requirements detailed in this policy.

 

PROCEDURE

 

Pfizer AH Customer Service will make pick up arrangements for returns of outdated product purchased directly from Pfizer. Veterinarians or Pfizer Territory Mangers should contact Customer Service to arrange for pick-up at 1-800-733-5500. Returns for all other classes of trade should be sent freight prepaid to the Pfizer Returns Center located in Lee's Summit, MO.

 

Customer Service and/or Pfizer Animal Health Territory Manager must complete the Merchandise Return Form (MRF) and forward along with the return shipment to the Pfizer Animal Health Returns Center at One Pfizer Way, Building 200, Lee's Summit, MO 64081. The MRF should be marked as credit or exchange. If the return shipment contains both product to be credited, and also product to be exchanged, a separate MRF should be completed for the credit and the exchange. Credit or exchange will be issued only upon receipt of the product at the Pfizer Animal Health Returns Center. Product should not be destroyed in the field. The product must have been purchased directly from Pfizer Animal Health and within the defined returns window.

 

Distributor accounts should fax a copy of the completed MRF to Major Accounts at 1-800-228-5176 for returns authorization. Once approved, a copy of the signed form will be faxed back to the distributor to be included in the return shipment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]